{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:13:05Z","timestamp":1793059985134,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","award":["WI219567"],"award-info":[{"award-number":["WI219567"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005039","name":"Leids Universitair Medisch Centrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005039","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005039","name":"Leiden University Medical Center","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005039","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Prolactinomas are the most prevalent functioning pituitary adenomas. They affect gonadal function as well as health-related quality of life (HRQoL). This study aimed to report healthcare utilization and costs, including their determinants, for prolactinoma patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Cross-sectional study of 116 adult prolactinoma patients in chronic care in a Dutch tertiary referral center. Patients completed four validated questionnaires, assessing healthcare utilization and costs over the previous 12\u00a0months (Medical Consumption Questionnaire), disease bother and needs (Leiden Bother and Needs Questionnaire Pituitary), HRQoL (Short Form-36), and self-reported health status (EuroQol 5D). Regression analyses were used to assess associations between disease-related characteristics and healthcare utilization and costs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Mean age was 52.0\u00a0years (SD 13.7) and median follow-up was 15.0\u00a0years (IQR 7.6\u201326.1). Patients visited the endocrinologist (86.2%), general practitioner (37.9%), and ophthalmologist (25.0%) most frequently. Psychological care was used by 12.9% of patients and 5% were admitted to hospital. Mean annual healthcare costs were \u20ac1928 (SD 3319), mainly for pituitary-specific medication (37.6% of total costs), hospitalization (19.4%) and specialist care (16.1%). Determinants for higher healthcare utilization and costs were greater disease bother and needs for support, lower HRQoL, elevated prolactin, and longer disease duration, while tumor size, hypopituitarism and adrenal insufficiency were not significantly associated with healthcare utilization and costs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Healthcare utilization and costs of prolactinoma patients are related to patient-reported HRQoL, bother by disease and needs for support. Therefore, addressing patients\u2019 HRQoL and needs is a way forward to improve efficiency of care and patients\u2019 health status.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11102-020-01089-1","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T20:02:51Z","timestamp":1602014571000},"page":"79-95","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Healthcare utilization and costs among prolactinoma patients: a cross-sectional study and analysis of determinants"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0001-4408","authenticated-orcid":false,"given":"Merel","family":"van der Meulen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2400-2070","authenticated-orcid":false,"given":"Amir H.","family":"Zamanipoor Najafabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2523-8707","authenticated-orcid":false,"given":"Daniel J.","family":"Lobatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6425-0135","authenticated-orcid":false,"given":"Wilbert B.","family":"van den Hout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3410-8701","authenticated-orcid":false,"given":"Cornelie D.","family":"Andela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1077-8273","authenticated-orcid":false,"given":"Ingrid M.","family":"Zandbergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1194-9866","authenticated-orcid":false,"given":"Alberto M.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5208-921X","authenticated-orcid":false,"given":"Wouter R.","family":"van Furth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6322-3859","authenticated-orcid":false,"given":"Thea P. M.","family":"Vliet Vlieland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5817-3594","authenticated-orcid":false,"given":"Nienke R.","family":"Biermasz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,6]]},"reference":[{"issue":"2","key":"1089_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ando.2012.03.039","volume":"73","author":"N Karavitaki","year":"2012","unstructured":"Karavitaki N (2012) Prevalence and incidence of pituitary adenomas. Ann Endocrinol (Paris) 73(2):79\u201380. https:\/\/doi.org\/10.1016\/j.ando.2012.03.039","journal-title":"Ann Endocrinol (Paris)"},{"key":"1089_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8122203","author":"I Samperi","year":"2019","unstructured":"Samperi I, Lithgow K, Karavitaki N (2019) Hyperprolactinaemia. J Clin Med. https:\/\/doi.org\/10.3390\/jcm8122203","journal-title":"J Clin Med"},{"issue":"8","key":"1089_CR3","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1212\/wnl.0000000000002252","volume":"86","author":"A Bala","year":"2016","unstructured":"Bala A, \u0141ojek E, Marchel A (2016) Cognitive functioning of patients with a PRL-secreting pituitary adenoma: a preliminary report. Neurology 86(8):731\u2013734. https:\/\/doi.org\/10.1212\/wnl.0000000000002252","journal-title":"Neurology"},{"issue":"3","key":"1089_CR4","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1046\/j.1365-2265.1997.2701073.x","volume":"47","author":"A Reavley","year":"1997","unstructured":"Reavley A, Fisher AD, Owen D, Creed FH, Davis JR (1997) Psychological distress in patients with hyperprolactinaemia. Clin Endocrinol (Oxf) 47(3):343\u2013348. https:\/\/doi.org\/10.1046\/j.1365-2265.1997.2701073.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"1089_CR5","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1007\/s11102-015-0636-7","volume":"18","author":"CD Andela","year":"2015","unstructured":"Andela CD, Scharloo M, Pereira AM, Kaptein AA, Biermasz NR (2015) Quality of life (QoL) impairments in patients with a pituitary adenoma: a systematic review of QoL studies. Pituitary 18(5):752\u2013776. https:\/\/doi.org\/10.1007\/s11102-015-0636-7","journal-title":"Pituitary"},{"issue":"2","key":"1089_CR6","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA (2011) Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96(2):273\u2013288. https:\/\/doi.org\/10.1210\/jc.2010-1692","journal-title":"J Clin Endocrinol Metab"},{"issue":"14","key":"1089_CR7","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1056\/nejm199410063311403","volume":"331","author":"J Webster","year":"1994","unstructured":"Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 331(14):904\u2013909. https:\/\/doi.org\/10.1056\/nejm199410063311403","journal-title":"N Engl J Med"},{"issue":"4","key":"1089_CR8","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/ncpendmet0160","volume":"2","author":"A Colao","year":"2006","unstructured":"Colao A, Di Sarno A, Guerra E, De Leo M, Mentone A, Lombardi G (2006) Drug insight: cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women. Nat Clin Pract Endocrinol Metab 2(4):200\u2013210. https:\/\/doi.org\/10.1038\/ncpendmet0160","journal-title":"Nat Clin Pract Endocrinol Metab"},{"issue":"3","key":"1089_CR9","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1210\/clinem\/dgz144","volume":"105","author":"AH Zamanipoor Najafabadi","year":"2020","unstructured":"Zamanipoor Najafabadi AH, Zandbergen IM, de Vries F, Broersen LHA, van den Akker-van Marle ME, Pereira AM, Peul WC, Dekkers OM, van Furth WR, Biermasz NR (2020) Surgery as a viable alternative first-line treatment for prolactinoma patients: a systematic review and meta-analysis. J Clin Endocrinol Metab 105(3):e32\u201341. https:\/\/doi.org\/10.1210\/clinem\/dgz144","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1089_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1530\/eje-18-0682","volume":"180","author":"AG Ioachimescu","year":"2019","unstructured":"Ioachimescu AG, Fleseriu M, Hoffman AR, Vaughan Iii TB, Katznelson L (2019) Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas. Eur J Endocrinol 180(1):31\u201340. https:\/\/doi.org\/10.1530\/eje-18-0682","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1089_CR11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1210\/jc.2009-1238","volume":"95","author":"OM Dekkers","year":"2010","unstructured":"Dekkers OM, Lagro J, Burman P, J\u00f8rgensen JO, Romijn JA, Pereira AM (2010) Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab 95(1):43\u201351. https:\/\/doi.org\/10.1210\/jc.2009-1238","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1089_CR12","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s12020-017-1444-9","volume":"59","author":"MY Xia","year":"2018","unstructured":"Xia MY, Lou XH, Lin SJ, Wu ZB (2018) Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis. Endocrine 59(1):50\u201361. https:\/\/doi.org\/10.1007\/s12020-017-1444-9","journal-title":"Endocrine"},{"issue":"1","key":"1089_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11102-019-01016-z","volume":"23","author":"J Honegger","year":"2020","unstructured":"Honegger J, Nasi-Kordhishti I, Aboutaha N, Giese S (2020) Surgery for prolactinomas: a better choice? Pituitary 23(1):45\u201351. https:\/\/doi.org\/10.1007\/s11102-019-01016-z","journal-title":"Pituitary"},{"key":"1089_CR14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.wneu.2015.10.090","volume":"87","author":"PR Jethwa","year":"2016","unstructured":"Jethwa PR, Patel TD, Hajart AF, Eloy JA, Couldwell WT, Liu JK (2016) Cost-Effectiveness analysis of microscopic and endoscopic transsphenoidal surgery versus medical therapy in the management of microprolactinoma in the United States. World Neurosurg 87:65\u201376. https:\/\/doi.org\/10.1016\/j.wneu.2015.10.090","journal-title":"World Neurosurg"},{"issue":"2","key":"1089_CR15","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1055\/s-0036-1592193","volume":"78","author":"CC Zygourakis","year":"2017","unstructured":"Zygourakis CC, Imber BS, Chen R, Han SJ, Blevins L, Molinaro A, Kahn JG, Aghi MK (2017) Cost-effectiveness analysis of surgical versus medical treatment of prolactinomas. J Neurol Surg B 78(2):125\u2013131. https:\/\/doi.org\/10.1055\/s-0036-1592193","journal-title":"J Neurol Surg B"},{"issue":"4","key":"1089_CR16","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/scs.0000000000003456","volume":"28","author":"L Duan","year":"2017","unstructured":"Duan L, Yan H, Huang M, Zhang Y, Gu F (2017) An economic analysis of bromocriptine versus trans-sphenoidal surgery for the treatment of prolactinoma. J Craniofac Surg 28(4):1046\u20131051. https:\/\/doi.org\/10.1097\/scs.0000000000003456","journal-title":"J Craniofac Surg"},{"issue":"6","key":"1089_CR17","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1007\/s11102-015-0654-5","volume":"18","author":"MS Broder","year":"2015","unstructured":"Broder MS, Neary MP, Chang E, Ludlam WH (2015) Incremental healthcare resource utilization and costs in US patients with Cushing's disease compared with diabetes mellitus and population controls. Pituitary 18(6):796\u2013802. https:\/\/doi.org\/10.1007\/s11102-015-0654-5","journal-title":"Pituitary"},{"issue":"1","key":"1089_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.4158\/ep14126.Or","volume":"21","author":"MS Broder","year":"2015","unstructured":"Broder MS, Neary MP, Chang E, Cherepanov D, Ludlam WH (2015) Burden of illness, annual healthcare utilization, and costs associated with commercially insured patients with Cushing disease in the United States. Endocr Pract 21(1):77\u201386. https:\/\/doi.org\/10.4158\/ep14126.Or","journal-title":"Endocr Pract"},{"issue":"5","key":"1089_CR19","doi-asserted-by":"publisher","first-page":"681","DOI":"10.4158\/ep10368.Or","volume":"17","author":"B Swearingen","year":"2011","unstructured":"Swearingen B, Wu N, Chen SY, Pulgar S, Biller BM (2011) Health care resource use and costs among patients with cushing disease. Endocr Pract 17(5):681\u2013690. https:\/\/doi.org\/10.4158\/ep10368.Or","journal-title":"Endocr Pract"},{"issue":"4","key":"1089_CR20","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s11102-013-0506-0","volume":"17","author":"MS Broder","year":"2014","unstructured":"Broder MS, Neary MP, Chang E, Cherepanov D, Katznelson L (2014) Treatments, complications, and healthcare utilization associated with acromegaly: a study in two large United States databases. Pituitary 17(4):333\u2013341. https:\/\/doi.org\/10.1007\/s11102-013-0506-0","journal-title":"Pituitary"},{"issue":"11","key":"1089_CR21","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1007\/bf03345306","volume":"27","author":"G Didoni","year":"2004","unstructured":"Didoni G, Grottol S, Gasco V, Battistini M, Ferone D, Giusti M, Ragazzoni F, Ruffo P, Ghigo E, Minuto F (2004) Cost-of-illness study in acromegalic patients in Italy. J Endocrinol Invest 27(11):1034\u20131039. https:\/\/doi.org\/10.1007\/bf03345306","journal-title":"J Endocrinol Invest"},{"issue":"12","key":"1089_CR22","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.18553\/jmcp.2015.21.12.1106","volume":"21","author":"H Placzek","year":"2015","unstructured":"Placzek H, Xu Y, Mu Y, Begelman SM, Fisher M (2015) Clinical and economic burden of commercially insured patients with acromegaly in the United States: a retrospective analysis. J Manag Care Spec Pharm 21(12):1106\u20131112. https:\/\/doi.org\/10.18553\/jmcp.2015.21.12.1106","journal-title":"J Manag Care Spec Pharm"},{"issue":"2","key":"1089_CR23","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1530\/eje-16-0623","volume":"176","author":"E Les\u00e9n","year":"2017","unstructured":"Les\u00e9n E, Granfeldt D, Houchard A, Dinet J, Berthon A, Olsson DS, Bj\u00f6rholt I, Johannsson G (2017) Comorbidities, treatment patterns and cost-of-illness of acromegaly in Sweden: a register-linkage population-based study. Eur J Endocrinol 176(2):203\u2013212. https:\/\/doi.org\/10.1530\/eje-16-0623","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"1089_CR24","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/s12020-019-01847-7","volume":"64","author":"DJ Lobatto","year":"2019","unstructured":"Lobatto DJ, van den Hout WB, Zamanipoor Najafabadi AH, Steffens ANV, Andela CD, Pereira AM, Peul WC, van Furth WR, Biermasz NR, Vliet Vlieland TPM (2019) Healthcare utilization and costs among patients with non-functioning pituitary adenomas. Endocrine 64(2):330\u2013340. https:\/\/doi.org\/10.1007\/s12020-019-01847-7","journal-title":"Endocrine"},{"issue":"1","key":"1089_CR25","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/cen.13156","volume":"86","author":"E Soto-Pedre","year":"2017","unstructured":"Soto-Pedre E, Newey PJ, Bevan JS, Greig N, Leese GP (2017) The epidemiology of hyperprolactinaemia over 20 years in the Tayside region of Scotland: the prolactin epidemiology, audit and research study (PROLEARS). Clin Endocrinol (Oxf) 86(1):60\u201367. https:\/\/doi.org\/10.1111\/cen.13156","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"1089_CR26","doi-asserted-by":"publisher","first-page":"5256","DOI":"10.1210\/jcem.86.11.8054","volume":"86","author":"A Di Sarno","year":"2001","unstructured":"Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, Di Somma C, Faggiano A, Lombardi G, Colao A (2001) Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab 86(11):5256\u20135261. https:\/\/doi.org\/10.1210\/jcem.86.11.8054","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"1089_CR27","doi-asserted-by":"publisher","first-page":"4721","DOI":"10.1210\/jc.2007-2758","volume":"93","author":"M Ono","year":"2008","unstructured":"Ono M, Miki N, Kawamata T, Makino R, Amano K, Seki T, Kubo O, Hori T, Takano K (2008) Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab 93(12):4721\u20134727. https:\/\/doi.org\/10.1210\/jc.2007-2758","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1089_CR28","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1210\/jc.2003-030979","volume":"89","author":"A Colao","year":"2004","unstructured":"Colao A, Vitale G, Cappabianca P, Briganti F, Ciccarelli A, De Rosa M, Zarrilli S, Lombardi G (2004) Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab 89(4):1704\u20131711. https:\/\/doi.org\/10.1210\/jc.2003-030979","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1089_CR29","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1227\/01.Neu.0000325725.77132.90","volume":"63","author":"N Fatemi","year":"2008","unstructured":"Fatemi N, Dusick JR, Mattozo C, McArthur DL, Cohan P, Boscardin J, Wang C, Swerdloff RS, Kelly DF (2008) Pituitary hormonal loss and recovery after transsphenoidal adenoma removal. Neurosurgery 63(4):709\u2013718. https:\/\/doi.org\/10.1227\/01.Neu.0000325725.77132.90 ((discussion 718-709)","journal-title":"Neurosurgery"},{"issue":"6","key":"1089_CR30","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s11102-018-0913-3","volume":"21","author":"DJ Lobatto","year":"2018","unstructured":"Lobatto DJ, Steffens ANV, Zamanipoor Najafabadi AH, Andela CD, Pereira AM, van den Hout WB, Peul WC, Vliet Vlieland TPM, Biermasz NR, van Furth WR (2018) Work disability and its determinants in patients with pituitary tumor-related disease. Pituitary 21(6):593\u2013604. https:\/\/doi.org\/10.1007\/s11102-018-0913-3","journal-title":"Pituitary"},{"key":"1089_CR31","unstructured":"Erasmus University Rotterdam: Institute for Medical Technology Assessment: Questionnaires for the measurement of costs in economic evaluations. https:\/\/www.imta.nl\/questionnaires\/."},{"issue":"3","key":"1089_CR32","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s11102-016-0707-4","volume":"19","author":"CD Andela","year":"2016","unstructured":"Andela CD, Scharloo M, Ramondt S, Tiemensma J, Husson O, Llahana S, Pereira AM, Kaptein AA, Kamminga NG, Biermasz NR (2016) The development and validation of the Leiden Bother and Needs Questionnaire for patients with pituitary disease: the LBNQ-Pituitary. Pituitary 19(3):293\u2013302. https:\/\/doi.org\/10.1007\/s11102-016-0707-4","journal-title":"Pituitary"},{"issue":"6","key":"1089_CR33","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware Jr","year":"1992","unstructured":"Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30(6):473\u2013483","journal-title":"Med Care"},{"issue":"11","key":"1089_CR34","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/s0895-4356(98)00097-3","volume":"51","author":"NK Aaronson","year":"1998","unstructured":"Aaronson NK, Muller M, Cohen PD, Essink-Bot ML, Fekkes M, Sanderman R, Sprangers MA, te Velde A, Verrips E (1998) Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. J Clin Epidemiol 51(11):1055\u20131068. https:\/\/doi.org\/10.1016\/s0895-4356(98)00097-3","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"1089_CR35","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"EuroQol Group","year":"1990","unstructured":"EuroQol Group (1990) EuroQol\u2014a new facility for the measurement of health-related quality of life. Health Policy 16(3):199\u2013208. https:\/\/doi.org\/10.1016\/0168-8510(90)90421-9","journal-title":"Health Policy"},{"issue":"11","key":"1089_CR36","doi-asserted-by":"publisher","first-page":"e553","DOI":"10.1016\/s2468-2667(19)30155-0","volume":"4","author":"D Zhu","year":"2019","unstructured":"Zhu D, Chung HF, Dobson AJ, Pandeya N, Giles GG, Bruinsma F, Brunner EJ, Kuh D, Hardy R, Avis NE, Gold EB, Derby CA, Matthews KA, Cade JE, Greenwood DC, Demakakos P, Brown DE, Sievert LL, Anderson D, Hayashi K, Lee JS, Mizunuma H, Tillin T, Simonsen MK, Adami HO, Weiderpass E, Mishra GD (2019) Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data. Lancet Public Health 4(11):e553\u2013e564. https:\/\/doi.org\/10.1016\/s2468-2667(19)30155-0","journal-title":"Lancet Public Health"},{"key":"1089_CR37","unstructured":"Centraal Bureau voor de Statistiek: Standaard Onderwijsindeling 2016\u2014Editie 2017\/\u201918. In. Centraal Bureau voor de Statistiek, Den Haag\/Heerlen, The Netherlands, (2018)"},{"key":"1089_CR38","unstructured":"UNESCO Institute for Statistics: International Standard Classification of Education, Fields of education and training 2013 (ISCED-F 2013)\u2014Detailed field descriptions. In. UNESCO Institute for Statistics, Montreal, Canada, (2015)"},{"key":"1089_CR39","unstructured":"Zorginstituut Nederland: Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg. In. Zorginstituut Nederland, Diemen, The Netherlands, (2016)"},{"key":"1089_CR40","unstructured":"Organisation for Economic Co-operation and Development: Purchasing power parities (PPP). https:\/\/data.oecd.org\/conversion\/purchasing-power-parities-ppp.htm (2019)."},{"key":"1089_CR41","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1471-2288-8-70","volume":"8","author":"I Shrier","year":"2008","unstructured":"Shrier I, Platt RW (2008) Reducing bias through directed acyclic graphs. BMC Med Res Methodol 8:70. https:\/\/doi.org\/10.1186\/1471-2288-8-70","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"1089_CR42","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s12020-015-0737-0","volume":"53","author":"MA Mart\u00ednez-Mombl\u00e1n","year":"2016","unstructured":"Mart\u00ednez-Mombl\u00e1n MA, G\u00f3mez C, Santos A, Porta N, Esteve J, \u00dabeda I, Halperin I, Campillo B, Guillaumet M, Webb SM, Resmini E (2016) A specific nursing educational program in patients with Cushing's syndrome. Endocrine 53(1):199\u2013209. https:\/\/doi.org\/10.1007\/s12020-015-0737-0","journal-title":"Endocrine"},{"key":"1089_CR43","doi-asserted-by":"publisher","first-page":"695820","DOI":"10.1155\/2013\/695820","volume":"2013","author":"T Haugland","year":"2013","unstructured":"Haugland T, Veenstra M, Vatn MH, Wahl AK (2013) Improvement in stress, general self-efficacy, and health related quality of life following patient education for patients with neuroendocrine tumors: a pilot study. Nurs Res Pract 2013:695820. https:\/\/doi.org\/10.1155\/2013\/695820","journal-title":"Nurs Res Pract"},{"issue":"1","key":"1089_CR44","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1530\/eje-16-1015","volume":"177","author":"CD Andela","year":"2017","unstructured":"Andela CD, Repping-Wuts H, Stikkelbroeck N, Pronk MC, Tiemensma J, Hermus AR, Kaptein AA, Pereira AM, Kamminga NGA, Biermasz NR (2017) Enhanced self-efficacy after a self-management programme in pituitary disease: a randomized controlled trial. Eur J Endocrinol 177(1):59\u201372. https:\/\/doi.org\/10.1530\/eje-16-1015","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1089_CR45","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s11102-013-0463-7","volume":"17","author":"E Hatipoglu","year":"2014","unstructured":"Hatipoglu E, Topsakal N, Atilgan OE, Alcalar N, Camliguney AF, Niyazoglu M, Cotuk HB, Kadioglu P (2014) Impact of exercise on quality of life and body-self perception of patients with acromegaly. Pituitary 17(1):38\u201343. https:\/\/doi.org\/10.1007\/s11102-013-0463-7","journal-title":"Pituitary"},{"issue":"3","key":"1089_CR46","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.jbmt.2019.01.006","volume":"23","author":"TRL Lima","year":"2019","unstructured":"Lima TRL, Kasuki L, Gadelha MR, Lopes AJ (2019) The effectiveness of a therapist-oriented home rehabilitation program for a patient with acromegaly: a case study. J Bodyw Mov Ther 23(3):634\u2013642. https:\/\/doi.org\/10.1016\/j.jbmt.2019.01.006","journal-title":"J Bodyw Mov Ther"},{"issue":"10","key":"1089_CR47","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1001\/jama.2018.1150","volume":"319","author":"I Papanicolas","year":"2018","unstructured":"Papanicolas I, Woskie LR, Jha AK (2018) Health care spending in the United States and other high-income countries. JAMA 319(10):1024\u20131039. https:\/\/doi.org\/10.1001\/jama.2018.1150","journal-title":"JAMA"},{"key":"1089_CR48","first-page":"D88","volume":"160","author":"P Groenewegen","year":"2016","unstructured":"Groenewegen P (2016) General practitioners as gatekeepers: Better health care than in countries with self-referral to specialists? Ned Tijdschr Geneeskd 160:D88","journal-title":"Ned Tijdschr Geneeskd"},{"issue":"1","key":"1089_CR49","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3109\/02813432.2010.537015","volume":"29","author":"M Velasco Garrido","year":"2011","unstructured":"Velasco Garrido M, Zentner A, Busse R (2011) The effects of gatekeeping: a systematic review of the literature. Scand J Prim Health Care 29(1):28\u201338. https:\/\/doi.org\/10.3109\/02813432.2010.537015","journal-title":"Scand J Prim Health Care"},{"key":"1089_CR50","unstructured":"Rijksinstituut voor Volksgezondheid en Milieu (RIVM): Kosten van ziekten 2017. https:\/\/statline.rivm.nl\/#\/RIVM\/nl\/dataset\/50050NED\/table?ts=1592149193432 (2019)."},{"key":"1089_CR51","unstructured":"Centraal Bureau voor de Statistiek: Gezondheid en zorggebruik; persoonskenmerken. https:\/\/opendata.cbs.nl\/statline\/#\/CBS\/nl\/dataset\/83005NED\/table?ts=1592073580866 (2020)."},{"issue":"4","key":"1089_CR52","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.tem.2020.01.004","volume":"31","author":"Y Macotela","year":"2020","unstructured":"Macotela Y, Triebel J, Clapp C (2020) Time for a new perspective on prolactin in metabolism. Trends Endocrinol Metab 31(4):276\u2013286. https:\/\/doi.org\/10.1016\/j.tem.2020.01.004","journal-title":"Trends Endocrinol Metab"},{"issue":"7","key":"1089_CR53","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s10198-017-0947-x","volume":"19","author":"LI van Lier","year":"2018","unstructured":"van Lier LI, Bosmans JE, van Hout HPJ, Mokkink LB, van den Hout WB, de Wit GA, Dirksen CD, Nies H, Hertogh C, van der Roest HG (2018) Consensus-based cross-European recommendations for the identification, measurement and valuation of costs in health economic evaluations: a European Delphi study. Eur J Health Econ 19(7):993\u20131008. https:\/\/doi.org\/10.1007\/s10198-017-0947-x","journal-title":"Eur J Health Econ"},{"issue":"2","key":"1089_CR54","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/s0149-2918(00)88295-8","volume":"21","author":"J Xuan","year":"1999","unstructured":"Xuan J, Kirchdoerfer LJ, Boyer JG, Norwood GJ (1999) Effects of comorbidity on health-related quality-of-life scores: an analysis of clinical trial data. Clin Ther 21(2):383\u2013403. https:\/\/doi.org\/10.1016\/s0149-2918(00)88295-8","journal-title":"Clin Ther"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-020-01089-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-020-01089-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-020-01089-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T10:21:26Z","timestamp":1633515686000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-020-01089-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,6]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["1089"],"URL":"https:\/\/doi.org\/10.1007\/s11102-020-01089-1","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,6]]},"assertion":[{"value":"26 September 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by the Medical Ethical Committee of the Leiden University Medical Center (No. p12.067).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}